Program
Estrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0117
Its studies are mostly in Breast Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Apr 6, 20261 company-led study, 1 open or runningNext primary completion: Apr 30, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Apr 6, 2026 | Apr 6, 2026 | Apr 30, 2028phase 1 · NCT07524855 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-4362 (HLD-0117)
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 6, 2026First study: phase 1 study in Breast NeoplasmsFirst studyNCT07524855 · 170 planned · United States, Australia
Ahead
- Apr 30, 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07524855
TargetBeta
“An orally bioavailable bifunctional small molecule composed of an estrogen receptor (ER)-binding moiety that is conjugated, via a linker, to a moiety that binds to an as of yet undisclosed pan-essential protein, with potential antineoplastic activity. Upon oral administration of ER-targeting regu…”NCIt, read by Claude
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07524855Breast Neoplasms · United States, Australia | 1 | Recruiting | Apr 30, 2028 | 170 |
How it is read
Names in the registry
- “JNJ-101684362 (HLD-0117)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.